{"title":"Pharmacokinetics of Quinocetone and Its Major Metabolites in Swine After Intravenous and Oral Administration","authors":"Jia-lin ZHONG, Gui-jun ZHANG, Xiang-guang SHEN, Lin WANG, Bing-hu FANG, Huan-zhong DING","doi":"10.1016/S1671-2927(11)60121-1","DOIUrl":null,"url":null,"abstract":"<div><p>The pharmacokinetics of quinocetone and its major metabolites in healthy swine was investigated in this paper. Quinocetone was administered to 8 healthy cross-bread swine intravenously and orally at a dosage of 4 and 40 mg kg<sup>−1</sup> body weight respectively in a randomized crossover design test with two-week washout period. A sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed for the determination of quinocetone and its metabolite 1-desoxyquinocetone in plasma. Plasma concentration versus time profiles of quinocetone and its metabolite 1-desoxy quinocetone were analyzed by non-compartmental analysis using Winnonlin 5.2 software. Mean maximum concentrations (C<sub>max</sub>) for quinocetone was found to be (0.56±0.13) μg mL<sup>−1</sup> at 2.92 h, after oral administration of quinocetone. Mean maximum concentrations (C<sub>max</sub>) for 1-desoxy quinocetone after intravenous or oral administration of quinocetone were (0.0095±0.0012) μg mL·<sup>1</sup> at 0.083 h and (0.0067±0.0053) μg mL<sup>−1</sup> at 3.08 h. The apparent elimination half-lives (T<sub>1/2</sub>) for quinocetone and its metabolite 1-desoxy quinocetone were (2.24±0.24) and (5.23±0.56) h after intravenous administration of quinocetone and (2.91±0.29) and (11.85±2.89) h after oral administration of quinocetone, respectively. Mean areas under the plasma concentration-time curve (AUC<sub>0-x</sub>) for quinocetone and 1-desoxyquinocetone were (2.02±0.15) and (0.2±0.002) μg h mL<sup>−1</sup> respectively after intravenous administration of quinocetone, and (3.5±0.79) and (0.053±0.03) μg h mL<sup>−1</sup> after oral administration of quinocetone, respectively. Quinocetone was rapidly absorbed and metabolized in swine after oral and intravenous administration. The plasma concentration-time curve (AUC<sub>0-x</sub>) of 1-desoxy quinocetone were much smaller than those of quinocetone, while the elimination half-lives (T<sub>1/2</sub>) were much longer than those of quinocetone after intravenously (i.v.) or oral administration.</p></div>","PeriodicalId":7475,"journal":{"name":"Agricultural Sciences in China","volume":"10 8","pages":"Pages 1292-1300"},"PeriodicalIF":0.0000,"publicationDate":"2011-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1671-2927(11)60121-1","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Agricultural Sciences in China","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1671292711601211","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 17
Abstract
The pharmacokinetics of quinocetone and its major metabolites in healthy swine was investigated in this paper. Quinocetone was administered to 8 healthy cross-bread swine intravenously and orally at a dosage of 4 and 40 mg kg−1 body weight respectively in a randomized crossover design test with two-week washout period. A sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed for the determination of quinocetone and its metabolite 1-desoxyquinocetone in plasma. Plasma concentration versus time profiles of quinocetone and its metabolite 1-desoxy quinocetone were analyzed by non-compartmental analysis using Winnonlin 5.2 software. Mean maximum concentrations (Cmax) for quinocetone was found to be (0.56±0.13) μg mL−1 at 2.92 h, after oral administration of quinocetone. Mean maximum concentrations (Cmax) for 1-desoxy quinocetone after intravenous or oral administration of quinocetone were (0.0095±0.0012) μg mL·1 at 0.083 h and (0.0067±0.0053) μg mL−1 at 3.08 h. The apparent elimination half-lives (T1/2) for quinocetone and its metabolite 1-desoxy quinocetone were (2.24±0.24) and (5.23±0.56) h after intravenous administration of quinocetone and (2.91±0.29) and (11.85±2.89) h after oral administration of quinocetone, respectively. Mean areas under the plasma concentration-time curve (AUC0-x) for quinocetone and 1-desoxyquinocetone were (2.02±0.15) and (0.2±0.002) μg h mL−1 respectively after intravenous administration of quinocetone, and (3.5±0.79) and (0.053±0.03) μg h mL−1 after oral administration of quinocetone, respectively. Quinocetone was rapidly absorbed and metabolized in swine after oral and intravenous administration. The plasma concentration-time curve (AUC0-x) of 1-desoxy quinocetone were much smaller than those of quinocetone, while the elimination half-lives (T1/2) were much longer than those of quinocetone after intravenously (i.v.) or oral administration.
本文研究了喹诺酮及其主要代谢物在健康猪体内的药动学。采用随机交叉设计试验,8头健康十字面包猪分别以4和40 mg kg - 1体重静脉滴注喹诺酮和口服喹诺酮,洗脱期为2周。建立了高效液相色谱-串联质谱(HPLC-MS/MS)测定血浆中喹诺酮及其代谢产物1-去氧喹诺酮的方法。采用Winnonlin 5.2软件对喹诺酮及其代谢物1-去氧喹诺酮的血药浓度随时间变化曲线进行非区隔分析。口服喹诺酮后2.92 h,喹诺酮的平均最大浓度(Cmax)为(0.56±0.13)μ mL−1。静脉或口服喹诺酮后1-去氧基喹诺酮的平均最大浓度(Cmax)分别为(0.0095±0.0012)μ mL·1 (0.083 h)和(0.0067±0.0053)μ mL·1 (3.08 h)。喹诺酮及其代谢物1-去氧基喹诺酮的表观消除半衰期(T1/2)分别为(2.24±0.24)和(5.23±0.56)h,口服喹诺酮后分别为(2.91±0.29)和(11.85±2.89)h。静脉给药喹诺酮和1-去氧喹诺酮的血药浓度-时间曲线下平均面积(AUC0-x)分别为(2.02±0.15)和(0.2±0.002)μg h mL - 1,口服喹诺酮后分别为(3.5±0.79)和(0.053±0.03)μg h mL - 1。喹诺酮经口服和静脉给药后在猪体内被迅速吸收和代谢。1-去氧喹诺酮的血药浓度-时间曲线(AUC0-x)比喹诺酮小得多,其消除半衰期(T1/2)比喹诺酮静脉(i.v)或口服给药要长得多。